SCFE Longitudinal International Prospective Registry

(SLIP Trial)

Overseen by Kishore Mulpuri, FRCSC

Age: < 65

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Academic

Recruiting

Sponsor: University of British Columbia

No Placebo Group

Trial Summary

What is the purpose of this trial?

Slipped Capital Femoral Epiphysis (SCFE) is the most common disorder of the adolescent hip and diagnosis and treatment of SCFE remain areas of controversy and investigation. The current issues relating to diagnosis stem from an inability to diagnose the condition early on, resulting in increased morbidity. Once diagnosed, there are multiple different options for surgical treatment, including in-situ pinning, and the Modified Dunn procedure. Research is ongoing to determine the parameters that should be considered when selecting a procedure to ensure an ideal outcome. In particular, there is a focus on investigating which treatment method may result in lower incidence of avascular necrosis of the femoral head and femoroacetabular impingement (FAI), two significant long term concerns associated with SCFE. Despite myriad published studies on SCFE, very few are prospective and most lack sufficient patient numbers for clinically meaningful comparative analysis. The aim of this study is to develop a multi-center, international prospective registry of patients with SCFE to facilitate the comprehensive examination of clinical, functional and radiographic outcomes of each treatment, in relation to specific parameters determined prior to intervention. The general registry will serve as a hypothesis-generating database of prospectively collected outcomes. In turn, this will facilitate the development of targeted, hypothesis-testing randomized controlled trials and observational studies that can be housed within the larger registry.

Research Team

Kishore Mulpuri, FRCSC

Principal Investigator

Principal Investigator

Eligibility Criteria

Inclusion Criteria

Confirmed diagnosis of SCFE

Intend to receiving follow-up at participating centre

Less than 18 years old at time of admission

Treatment Details

Interventions

• Observational (Other)

Participant Groups

Group I: Arm III: Prior treatment at outside centre Experimental Treatment 1 Intervention

Patients who have received previous treatment at an outside center but are continuing treatment at a participating center will be placed into Arm III.

Group II: Arm II: Prior treatment at centre Experimental Treatment 1 Intervention

Patients who have received previous treatment and will continue to receive treatment at the participating center will be placed into Arm II.

Group III: Arm I: Prospective from diagnosis Experimental Treatment 1 Intervention

Patients have been enrolled and followed since diagnosis will be placed into Arm I.

Who Is Running the Clinical Trial?

University of British Columbia

Lead Sponsor

Trials

1,506

Recruited

2,528,000+

Dr. Christopher Haqq

University of British Columbia

Chief Medical Officer since 2019

MD, University of British Columbia

Bekki Bracken Brown

University of British Columbia

Chief Executive Officer since 2023

Bachelor's degree from Duke University